| Expression pattern: |
UP |
| Associated gene: |
KRAS |
| Associated microRNA: |
hsa-miR-1182, hsa-miR-1208, hsa-miR-1290, hsa-miR-1299, hsa-miR-140-3p, hsa-miR-494-3p, hsa-miR-622 |
| Biological function: |
promotes HCC progression by promoting cell proliferation and migration; mediates lenvatinib resistance |
| Molecular mechanism: |
ceRNA mechanism: hsa_circ_0001726 binds miR-140-3p and regulates KRAS |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); ceRNA regulation (other); drug resistance (promotes) |
| Detected method: |
Q
S
M
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Luciferase Reporter Assay; RNA Pull-Down; Transfection; EdU Staining; Transwell Assay; Survival Analysis; Bioinformatics Analysis; Microarray; RNA-seq |
| Clinical significance: |
high hsa_circ_0001726 expression predicts worse overall survival and is a prognostic factor in HCC |
| Description: |
hsa_circ_0001726 is up-regulated in HCC tissues and cells and promotes HCC proliferation and migration. It functions through a ceRNA axis involving miR-140-3p and KRAS, and contributes to lenvatinib resistance. High hsa_circ_0001726 expression is associated with worse overall survival in HCC patients. |
| Confidence score: |
0.7752 |